Editas Medicine to Present Preclinical Data Demonstrating Advancements in In Vivo Gene Editing Approach for the Treatment of Genetic Ocular Diseases at the Association for Research in Vision and Ophthalmology Annual Meeting
CAMBRIDGE, Mass., May 01, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that two scientific abstracts have been accepted for presentation at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting being held virtually May 1 – 7, 2021. The Company is presenting preclinical data on its Usher Syndrome 2A (USH2A) and retinitis pigmentosa 4 (RP4) programs.
Editas Medicine’s presentations at ARVO will include preclinical data demonstrating:
“Editas Medicine is making significant advancements in our efforts to treat ocular diseases, and we look forward to sharing recent progress and preclinical data on our USH2A and RP4 programs this week at the ARVO Annual Meeting,” said Kate Zhang, Vice President, Biological Development, Editas Medicine. “This data further supports our advancing these programs towards the clinic and our belief in the potential for gene editing medicines to transform the lives of those living with inherited retinal diseases.”
The complete list of Editas Medicine presentations is below. Abstracts can be accessed on the ARVO website at https://arvo2021.arvo.org/abstracts.
About Editas Medicine
Contacts: Media Cristi Barnett (617) 401-0113 email@example.com Investors Ron Moldaver (617) 401-9052 firstname.lastname@example.org
Great Customer Outcomes: A Balance Between Automation & Empathy
How SASE is Your Security Strategy?
The New World of Remote Work